REGN Regeneron Pharmaceuticals Inc.

+5.64  (+2%)
Previous Close 292.56
Open 292.98
Price To Book 3.46
Market Cap 32,694,281,810
Shares 109,638,772
Volume 875,947
Short Ratio
Av. Daily Volume 910,423

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced September 28, 2018.
Cutaneous squamous cell carcinoma
FDA Approval announced August 17, 2018.
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 data due 4Q 2019.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Pivotal Phase 2/3 trial ongoing.
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
Non-small cell lung cancer (NSCLC)
Data due 2020.
Basal cell carcinoma
Phase 2 enrolling as of September 2017. BLA filing due 1Q 2018 pending data.
Basal cell carcinoma
Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only.
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
Respiratory syncytial virus (RSV)
FDA Approval announced May 13, 2019.
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
Diabetic Retinopathy
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
FDA Approval announced June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Osteoarthritis and chronic low back pain
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 3 trial commenced September 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Rheumatoid arthritis
Phase 2 trial to commence June 2019. Updated Phase 1 data EHA June 14, 2019 noted 93% ORR in follicular lymphoma, 57% ORR in DLBCL.
Non-Hodgkin Lymphoma (NHL)
Phase 3 data due 2019.
Evinacumab (ANGPTL3 Antibody)
Homozygous familial hypercholesterolemia (HoFH)
Phase 2 data due 1Q 2020.
Chronic Obstructive Pulmonary Disease (COPD)
Phase 2 data June 21, 2019 met primary endpoint vs placebo. No increased benefit compared to Dupixent.
SAR440340 (REGN3500)

Latest News

  1. Stocks That Fell to 3-Year Lows in the Week of July 12
  2. 4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
  3. FDA Accepts Sanofi's BLA for Myeloma Candidate to Review
  4. US Market Indexes Higher on Wednesday
  5. David Herro and Bill Nygren Comment on Regeneron Pharmaceuticals
  6. David Herro and Bill Nygren's 2nd Quarter Oakmark Global Select Fund Commentary
  7. Why Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Looks Like A Quality Company
  8. Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019
  9. Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
  10. Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
  11. Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
  12. Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
  13. Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
  14. 3 Top Biotech Stocks to Add to Your Watchlist
  15. Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
  16. UPDATE 2-FDA approves expanded label for Regeneron/Sanofi's Dupixent
  17. FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
  18. FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
  19. Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
  20. The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart